THE DEMOGRAPHICS OF ANTIBIOTIC ADVERSITY: UNRAVELING ADRS IN PEDIATRIC CARE

Main Article Content

Mohd Shadab
Jyotsna Sharma
Rajni Kumari Rai
Shaktibala Dutta

Keywords

Adverse Drug Reactions, Antibiotics, Pediatrics, Gender Disparities, Age Differences, Drug Safety

Abstract

Background: Adverse Drug Reactions (ADRs) are a significant concern in pediatric healthcare, potentially leading to increased morbidity and healthcare costs. This study aimed to characterize ADRs to antibiotics among pediatric patients, focusing on age and gender disparities.


Methods: A prospective observational study was conducted over 11 months at a tertiary care hospital involving 300 pediatric patients aged 28 days to 18 years. Antibiotics were prescribed according to standard treatment guidelines, and ADRs were assessed using the WHO causality assessment scale. Data were analyzed using IBM SPSS Statistics 25.


Results: A total of 34 ADRs were observed, with a higher prevalence in males (61.76%) compared to females (38.23%). The age group of 17-18 years exhibited the most ADRs (44.11%). Penicillins were the leading cause of ADRs (67.64%), followed by cephalosporins, macrolides, fluoroquinolones, and lincosamides. The most common ADRs were thrombophlebitis, eosinophilia, vomiting, and abdominal pain. Recovery from ADRs during the hospital stay was 100%.


Conclusion: The study highlights significant age and gender disparities in ADRs to antibiotics in pediatric patients, with adolescent males being the most affected group. These findings suggest the need for age and gender-specific considerations in antibiotic prescribing practices to enhance patient safety.

Abstract 28 | pdf Downloads 16

References

1. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52(1):77-83.
2. Smyth RM, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, et al. Adverse drug reactions in children—a systematic review. PLoS One. 2012;7(3):e24061.
3. Zito JM, Burcu M, Ibe A, Safer DJ, Magder LS. Antipsychotic use by Medicaid-insured youths: Impact of eligibility and psychiatric diagnosis across a decade. Psychiatr Serv. 2013;64(3):223-229.
4. Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caudri D, et al. Drug use in children: cohort study in three European countries. BMJ. 2008;337:a2245.
5. The use of the WHO-UMC system for standardized case causality assessment [Internet]. Uppsala: The Uppsala Monitoring Centre; 2013 [cited 2023 Nov 9]. Available from: https://www.who-umc.org/media/2768/standardised-case-causality-assessment.pdf.
6. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143-57.
7. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol. 2001;2(6):349-51.
8. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-67.
9. Anderson GD, Lynn AM. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy. 2009;29(6):680-90.
10. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child. 2009;94(9):724-8.